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Introduction:  Simultaneous  bilateral  total  knee  arthroplasty  (TKA)  is proposed  in the  general  population
as  an alternative  to  staged  bilateral  TKA and  has  the  advantage  of  reducing  costs  with  equivalent  compli-
cation  rates.  The  aim of  this  study  was  to evaluate  the  cost-effectiveness  of  this  alternative  in a  population
of  patients  with  severe  hemophilia.
Hypothesis:  Simultaneous  bilateral  TKA  is  less  expensive  than  staged  bilateral  TKA.
Materials and methods:  We  performed  a retrospective  case  control  study  in  patients  with  severe
hemophilia  A to compare  the direct  costs  of coagulation  factors,  the  length  of  hospital  stay  and  sick
leave  as well  as  the  clinical  outcome  (KKS)  of  simultaneous  bilateral  TKA  (group  1;  G1:  5  patients)  and
staged  bilateral  TKA  (group  2; G2: 12 patients).
Results:  The  mean  cost  of coagulation  factors  was  65,880  D in  G1  and  139,000  D in  G2  (P  <  0.001).  The
length  of the  hospital  stay  (24 days  vs  44  cumulative  days,  respectively)  and  sick  leave  (105  days  vs  183
cumulative  days,  respectively)  was  signiﬁcantly  reduced  in  G1.  There  was  no  signiﬁcant  difference  in
clinical  outcome  at the  ﬁnal  follow-up.  One  patient  in G2 had  a late  knee  infection.
Discussion:  Simultaneous  bilateral  TKA  in  severe  hemophilia  is  associated  with  lower  costs  than  staged
bilateral  TKA  with  equivalent  clinical  results.
Level of evidence:  Level  3, case  control  study.
©  2015  Elsevier  Masson  SAS.  All  rights  reserved.. Introduction
In the general population, simultaneous bilateral total knee
rthroplasty (TKA) has sometimes been associated with certain
isks including increased morbidity [1] with, in particular, an
ncrease in myocardial infarction and thromboembolic events [2]
r perioperative confusion [3] in patients over the age of 80 or ASA
 or 4 [3,4]. Continuous improvement of perioperative manage-
ent has reduced the number of adverse events so that certain
uthors have re-evaluated the controversial issues associated with
his procedure, and recent studies have not reported any increase
n complications in selected patients [5–8].
TKA is a well-tolerated and effective technique in patients with
evere hemophilia (factor VIII < 1%) with good long-term results
9–11]. Moreover, the episodes of hemarthrosis are reduced and
∗ Corresponding author.
E-mail address: andre.thes@gmail.com (A. Thès).
http://dx.doi.org/10.1016/j.otsr.2014.12.010
877-0568/© 2015 Elsevier Masson SAS. All rights reserved.thus there is a decrease in the consumption of coagulation factors,
which are very expensive [12].
In patients with severe hemophilia, TKA is usually indicated
when the patient is in his thirties [13,14]. Because lesions are usu-
ally bilateral, in young patients without comorbidities other than
the causal disease, simultaneous bilateral TKA is indicated, so the
patient can return to his professional activities as quickly as possi-
ble.
The simultaneous bilateral procedure also has the advantage
of limiting the consumption of coagulation factors, resulting in a
signiﬁcant reduction of costs because these factors are expensive,
and because of the quantities necessary in patients with severe
hemophilia.
The goal of this study was  to compare the direct costs of coagula-
tion factors during simultaneous bilateral TKA compared to staged
bilateral TKA in patients with severe hemophilia. We  also evalu-
ated the length of the hospital stay, the length of sick leave and the
clinical outcome.
Hypothesis: simultaneous bilateral TKA is less expensive than
staged bilateral TKA in patients with severe hemophilia.
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. Materials and methods
This retrospective study was performed in a University Hospi-
al Center (CHU de Bicêtre, AP–HP, Kremlin-Bicêtre) between 2006
nd 2013 and included patients with severe hemophilia with an
ncapacitating bilateral hemophiliac arthropathy. All patients in
hom both knees were operated on were included in the study.
ive patients underwent simultaneous bilateral TKA (group 1, G1)
nd twelve patients underwent staged bilateral TKA (group 2, G2).
atients in G1 were eligible for simultaneous bilateral TKA because
hey had symmetric involvement at the time of the initial consul-
ation, followed by a discussion between the surgeon (VM) and the
eferring hematologist (TL) and the patient’s consent to undergo a
erious operation. Inclusion in G1 or G2 was not consecutive. The
ean age at surgery was 33.5 years old (23–39 years) in G1 and 37.2
ears old for the ﬁrst operation (27–54 years old) in G2. The mean
elay between the 2 procedures in G2 was 21.5 months (range:
–74 months). The mean follow-up was 4.8 years in G1 and 4.1
ears after the second operation in G2. The two groups were com-
arable for age, Knee Society Score (KSS) and preoperative range of
otion (Table 1). There was no difference between any of the two
nees in the same patient.
.1. Factor replacement therapy
Factor replacement therapy was adapted to each patient accord-
ng to weight, with daily adjustment by the Reference Center for the
reatment of Hemophilia (Centre de référence pour le traitement
e l’hémophilie) (CRTH, CHU de Bicêtre) for at least 21 days. The tar-
eted residual FVII activity levels or the clinical target in patients
eceiving an inhibitor were the same for G1 as those for unilateral
KA.
.2. Surgical procedure
All procedures were performed without a tourniquet by antero-
edial approach with a V-Y quadricipital plasty in case of
evere stiffness. Prostheses (Ceragyr or Hermes–Ceraver, Roissy,
rance) were cemented with antibiotic-loaded cement (Palacos
enta–Heraeus Medical GmbH, Wehrheim, Germany). There was
o patellar resurfacing (Fig. 1). The incision was closed on Redon
rains and a pressure dressing was applied. The patients were
iven locoregional analgesia via a unilateral or bilateral femoral
erineural catheter. Rehabilitation began on postoperative day 1
ith the help of a physical therapist and continuous passive motion
y arthromotor alternating from one knee to the other in G1. The
rains were removed a mean 5 days after surgery (range: 3–10
ays) in both groups.
.3. EvaluationThe main judgment criteria were the direct costs of replace-
ent factors determined by the dose received during the initial
ospital stay. The purchase price of these drugs in 2013 by the
eneral Agency for Medical Products (AGEPS: Agence générale des
able 1
omparison of populations before surgery.
Group 1 (n = 5) Group 2 (n = 12)
Age (years) 33.5 (23–39) 37.2 (27–54)
Presence of inhibitors 1 0
KSS (knee score) 13 (0–27) 14.6 (0–28)
KSS (function score) 22 (0–45) 23.7 (0–50)
Range of motion 43◦ (0–50) 47◦ (10–65)
SS: Knee Society Score.urgery & Research 101 (2015) 147–150
produits de santé–AP–HP, Paris) was  720 D for 1000 UI  of factor VIII
(Helixate® – CSL Behring or Advate® – Baxter) and 608 D for 1 mg
of factor VII (Novoseven® – Novo Nordisk). The length of the hos-
pital stay and the date of the return to work were recorded, using
the sum of the stays for both operations in G2. Evaluation of func-
tion was obtained by the pre- and postoperative Knee Society Score
(KSS – former version [15]) until the ﬁnal follow-up. Results were
the sum of the mean right and left knee scores on one hand and
the function score on the other. Severe adverse events included
death, surgical revision due to infection, hemarthrosis, fracture or
loosening.
2.4. Statistical analysis
The statistical analysis was performed with BiostaTGV software
– Inserm, France. Comparison of the costs of replacement therapy
during hospitalization, the length of the hospital stay and sick leave
were performed with the Wilcoxon–Mann–Whitney test. P < 0.05
was considered to be signiﬁcant.
3. Results
During the hospital stay a mean 91,500 UI (65,880 D) of factor
VIII was  administered per person to patients without circulating
antibodies in G1 compared to 193,250 UI (or 139,000 D) of factor
VIII in G2 (P < 0.01). The cost of replacement therapy was 766,000 D
(1260 mg  de Novoseven®) for the patient with circulating antibod-
ies (Table 2). The mean length of the hospital stay was 24 days
(range 21–26) in G1 and the cumulative hospital stay was 44 days
in two  hospital stays in G2 (range 39–50) (P < 0.01). The patient
returned to work after a mean 105 postoperative days (range
90–120) in G1 and after a mean 183 cumulative days in G2 (range
150–210) (P < 0.01). Three patients in G1 received a transfusion
during their hospital stay and 9 in G2 (P = 0.6). No severe adverse
events were observed during the initial hospital stay. There were
no early revision surgeries during hospitalization. One patient in G1
underwent manipulation under anesthesia for stiffness on postop-
erative day 60, which did not improve in one of the two  knees.
There were no infections or other complications in G1. In G2, one
case of infection of the prosthesis and two hemarthroses required
surgical treatment. The mean KSS at the ﬁnal follow-up was 158.4
for G1 and 155.6 for G2 (P = 0.6). All patients who  underwent simul-
taneous TKA stated that they were satisﬁed and would repeat the
operation, but they described the ﬁrst postoperative week as very
difﬁcult, with nearly total dependency.
4. Discussion
Simultaneous bilateral TKA is a serious operation that is indi-
cated in patients with severe hemophilia due to the bilateral
involvement, which is extremely incapacitating in young patients.
In the general population, Reuben et al. observed a decrease of 36%
in the cost of simultaneous bilateral TKA compared to two staged
operations [16]. Odum et al estimated that the hospital costs of
simultaneous bilateral TKA were 45,000 $ compared to 72,000 $ for
a series of 2 operations [17].
In patients with severe hemophilia presenting with involve-
ment of both knees, the cost of replacement therapy for
simultaneous bilateral TKA is nearly twice as inexpensive as that for
staged bilateral TKA. The savings are even greater in patients with
inhibitors, for whom the cost of replacement therapy is especially
high: the estimated cost in the literature of a single TKA in these
cases is more than 850,000 $ [12] which is comparable to the results
in our study. The total length of the hospital stay was  also nearly
twice as short and the sick leave was also signiﬁcantly reduced. The
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verall savings must still be evaluated but seem to be signiﬁcant,
ell above the cost of replacement therapy alone.
Although our study is limited by the small size of the study pop-
lation, which is obviously because this was a single center study in
 rare disease, to our knowledge, this is the ﬁrst study to speciﬁcally
valuate simultaneous bilateral TKA in hemophilia. The functional
utcome of the two groups is comparable and the use of a simulta-
eous procedure or two operations did not inﬂuence the long-term
utcome.
Most of the series in the literature agree that TKA provides a real
eneﬁt to patients with hemophilia, mainly for pain relief but also
or ﬂexion and range of motion [18], which we also found in our
tudy. An increase in morbidity has been described in hemophil-
ac patients compared to non-hemophiliac patients following TKA,
ith, in particular, a higher rate of implant infection [11,19,20].
able 2
esults at ﬁnal follow-up.
Group 1 (n = 5) 
Cost of substitution factors (euros) 65,880 (766,000 with inhib
Length  of hospital stay (days) 24 
Length  of sick leave (days) 105 
Complications (number of events) 0 
KSS  at ﬁnal follow-up 158.4 
Mean  knee scores 86.8 
Mean function scores 71.6 
SS: Knee Society Score.of a patient with bilateral simultaneous knee arthroplasty; immediate postoperative
No increase in morbidity was  observed with simultaneous bilat-
eral TKA in our study, which is comparable to the existing results
of bilateral TKA in healthy subjects in the literature [7,8,17,21].
The latter’s studies even suggest that simultaneous bilateral TKA
is preferable to a staged procedure and provides better functional
results [17] in selected patients. Certain studies have reported a
decrease in the rate of infection and a faster return to work with
simultaneous bilateral TKA compared to the cumulative rates of
staged bilateral procedures [22].
Even if all of the patients who  underwent simultaneous bilateral
TKA declared that they were satisﬁed with the procedure, they all
stated that the immediate postoperative period was  extremely dif-
ﬁcult. We  did not evaluate whether the consumption of analgesics
was increased or the presence of postoperative depression. Nev-
ertheless before proposing this procedure, the patient should be
Groupe 2 (n = 12)
itor) 139,000 P < 0.01
44 P < 0.01
183 P < 0.01
3 P = 0.6
155.6 P = 0.6
84.8
70.8
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arefully selected for his psychological proﬁle, carefully informed
nd truly motivated.
In conclusion, simultaneous bilateral TKA in patients with
evere hemophilia is signiﬁcantly less expensive, with a shorter
ean hospital stay and faster return to work, with no severe com-
lications or change in functional results.
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